TABLE 1.
Sex/cancer site or type | All racial/ethnic groups | Non‐Hispanic White | Non‐Hispanic Black | Non‐Hispanic API | Non‐Hispanic AI/AN, PRCDA | Hispanic | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rank | Rate (95% CI) | AAPC (95% CI) | p | Rate (95% CI) | AAPC (95% CI) | p | Rate (95% CI) | AAPC (95% CI) | p | Rate (95% CI) | AAPC (95% CI) | p | Rate (95% CI) | AAPC (95% CI) | p | Rate (95% CI) | AAPC (95% CI) | p | |
All sites f | |||||||||||||||||||
Both sexes | 457.5 (457.2–457.8) | −0.2 (−0.5, 0.1) | .19 | 477.9 (477.5–478.3) | 0.0 (−0.4, 0.3) | .91 | 467.8 (466.8–468.8) | −0.7 (−1.1, −0.4) g | < .001 | 305.5 (304.3–306.6) | −0.3 (−0.3, −0.2) g | < .001 | 488.3 (482.9–493.8) | 0.6 (0.4–0.8) g | < .001 | 358.7 (357.9–359.6) | −0.1 (−0.4, 0.2) | .58 | |
Males | 497.4 (497.0–497.9) | −0.4 (−1.2, 0.3) | .22 | 514.2 (513.6–514.7) | −0.2 (−0.9, 0.5) | .55 | 544.0 (542.4–545.7) | −1.2 (−1.8, −0.5) g | .004 | 306.3 (304.5–308.1) | −1.2 (−1.4, −1.1) g | < .001 | 515.0 (506.5–523.6) | 0.0 (−0.3, 0.3) | .86 | 384.0 (382.7–385.4) | −0.9 (−1.3, −0.5) g | < .001 | |
Females | 430.9 (430.4–431.3) | 0.2 (0.1–0.3) g | < .001 | 454.0 (453.5–454.5) | 0.3 (0.2–0.4) g | < .001 | 416.7 (415.4–417.9) | −0.3 (−0.7, 0.0) | .07 | 309.1 (307.5–310.6) | 0.6 (0.6–0.7) g | < .001 | 473.3 (466.1–480.5) | 1.1 (0.9–1.3) g | < .001 | 346.7 (345.6–347.8) | 0.7 (0.5–0.9) g | < .001 | |
Children, ages 0–14 years | 17.8 (17.7–18.0) | 0.0 (−1.6, 1.6) | 1.00 | 18.7 (18.5–18.9) | 1.0 (0.8–1.2) g | < .001 | 13.8 (13.5–14.2) | 0.0 (−1.1, 1.1) | .97 | 17.2 (16.6–17.9) | 2.3 (1.9–2.7) g | < .001 | 19.2 (17.4–21.2) | 1.9 (0.6–3.2) g | .006 | 17.6 (17.3–17.9) | 0.8 (0.6–1.1) g | < .001 | |
AYAs, ages 15–39 years | 77.9 (77.6–78.1) | 0.9 (0.8–1.0) g | < .001 | 86.0 (85.7–86.4) | −0.2 (−1.5, 1.2) | .82 | 64.8 (64.2–65.4) | −0.7 (−2.2, 0.8) | .34 | 58.8 (58.0–59.6) | 1.0 (0.3–1.6) g | .008 | 90.0 (86.4–93.7) | 2.1 (1.6–2.6) g | < .001 | 65.8 (65.3–66.3) | 2.4 (2.0–2.9) g | < .001 | |
Males | |||||||||||||||||||
Prostate | 1 | 110.5 (110.3–110.7) | 3.0 (−1.1, 7.2) | .13 | 104.9 (104.6–105.1) | 3.7 (−0.8, 8.3) | .09 | 182.0 (181.1–183.0) | 1.6 (−1.1, 4.5) | .22 | 58.8 (58.0–59.6) | 4.4 (1.1–7.7) g | .01 | 89.1 (85.5–92.7) | 0.7 (−2.8, 4.3) | .67 | 96.0 (95.4–96.7) | 0.5 (−2.0, 3.2) | .65 |
Lung and bronchus | 2 | 66.1 (66.0, 66.3) | −2.6 (−2.7, −2.4) g | < .001 | 70.0 (69.8–70.2) | −2.8 (−3.2, −2.3) g | < .001 | 78.3 (77.7–79.0) | −3.2 (−3.5, −2.9) g | < .001 | 43.3 (42.7–44.0) | −1.5 (−1.7, −1.3) g | < .001 | 73.0 (69.7–76.3) | −5.3 (−9.9, −0.6) g | .03 | 34.9 (34.5–35.3) | −2.7 (−2.9, −2.5) g | < .001 |
Colon and rectum | 3 | 44.2 (44.0–44.3) | −1.2 (−1.6, −0.7) g | < .001 | 43.9 (43.7–44.0) | −1.2 (−1.5, −0.8) g | < .001 | 52.6 (52.0–53.1) | −2.7 (−2.9, −2.5) g | < .001 | 35.9 (35.3–36.5) | −2.0 (−2.3, −1.8) g | < .001 | 60.6 (57.7–63.6) | −0.2 (−0.9, 0.4) | .48 | 41.9 (41.4–42.3) | −2.0 (−2.3, −1.8) g | < .001 |
Urinary bladder | 4 | 34.6 (34.4–34.7) | −2.1 (−2.9, −1.2) g | < .001 | 39.0 (38.9–39.2) | −2.0 (−2.8, −1.2) g | < .001 | 19.8 (19.5–20.1) | −1.7 (−2.9, −0.4) g | .01 | 15.2 (14.8–15.7) | −0.7 (−0.9, −0.4) g | < .001 | 27.0 (24.9–29.2) | 1.8 (0.9–2.7) g | .001 | 18.8 (18.5–19.1) | −1.4 (−1.6, −1.2) g | < .001 |
Melanoma of the skin | 5 | 29.3 (29.2–29.4) | 0.5 (−1.6, 2.6) | .62 | 37.9 (37.7–38.0) | 2.5 (2.2–2.7) g | < .001 | 1.1 (1.1–1.2) | −0.3 (−1.3, 0.6) | .50 | 1.6 (1.5–1.8) | −0.1 (−0.7, 0.4) | .62 | 13.6 (12.2–15.2) | −4.1 (−10.1, 2.3) | .20 | 5.1 (5.0–5.3) | 0.3 (−0.2, 0.9) | .23 |
Non‐Hodgkin lymphoma | 6 | 23.7 (23.6–23.8) | −0.9 (−1.7, −0.1) g | .03 | 25.0 (24.9–25.2) | −0.8 (−1.5, −0.1) g | .02 | 17.9 (17.6–18.2) | 0.2 (−0.1, 0.4) | .15 | 16.5 (16.1–16.9) | 0.4 (0.1–0.7) g | .03 | 20.1 (18.5–21.9) | 0.0 (−1.0, 1.0) | .97 | 20.4 (20.1–20.7) | 0.1 (−0.2, 0.4) | .54 |
Kidney and renal pelvis | 7 | 23.6 (23.5–23.7) | 0.7 (0.4–1.1) g | < .001 | 24.0 (23.9–24.2) | 1.0 (0.4–1.6) g | .001 | 26.7 (26.3–27.1) | −1.4 (−3.3, 0.5) | .15 | 11.7 (11.3–12.0) | 0.7 (−0.4, 1.7) | .19 | 41.7 (39.4–44.1) | 2.6 (1.7–3.5) g | < .001 | 21.8 (21.5–22.1) | 0.8 (−1.0, 2.7) | .37 |
Leukemia | 8 | 19.5 (19.4–19.6) | −0.6 (−1.4, 0.1) | .10 | 20.9 (20.8–21.0) | −1.0 (−2.3, 0.3) | .11 | 14.8 (14.5–15.1) | 0.9 (0.4–1.3) g | < .001 | 11.0 (10.7–11.3) | 0.6 (−0.7, 1.9) | .33 | 17.7 (16.2–19.4) | 1.4 (0.4–2.5) g | .01 | 14.4 (14.2–14.7) | 0.7 (0.3–1.1) g | .002 |
Oral cavity and pharynx | 9 | 18.4 (18.3–18.5) | 0.2 (−1.2, 1.7) | .73 | 20.5 (20.3–20.6) | 0.7 (−0.7, 2.1) | .34 | 14.0 (13.8–14.3) | −1.9 (−2.1, −1.6) g | < .001 | 12.2 (11.8–12.5) | 0.9 (0.5–1.3) g | < .001 | 19.6 (18.1–21.3) | 2.3 (1.2–3.4) g | < .001 | 11.2 (11.0–11.4) | −0.5 (−0.8, −0.1) g | .01 |
Pancreas | 10 | 15.1 (15.0–15.2) | 1.1 (1.0–1.2) g | < .001 | 15.3 (15.2–15.4) | 1.3 (1.2–1.4) g | < .001 | 18.0 (17.7–18.3) | 0.7 (0.4–0.9) g | < .001 | 10.5 (10.2–10.9) | 0.6 (0.3–0.9) g | .001 | 16.7 (15.2–18.3) | 2.6 (1.2–4.0) g | .001 | 12.3 (12.0–12.5) | 0.6 (0.3–0.8) g | < .001 |
Liver and intrahepatic bile duct | 11 | 13.4 (13.3–13.4) | 0.4 (−0.5, 1.3) | .42 | 11.2 (11.1–11.3) | 1.3 (0.5–2.1) g | .003 | 18.2 (17.9–18.5) | −2.3 (−4.7, 0.2) | .07 | 19.6 (19.1–20.0) | −2.1 (−3.1, −1.1) g | .001 | 27.9 (26.1–29.8) | 4.6 (3.3–6.0) g | < .001 | 20.1 (19.8–20.4) | 0.4 (−0.3, 1.1) | .25 |
Myeloma | 12 | 9.2 (9.1–9.2) | 0.0 (−0.8, 0.9) | .97 | 8.3 (8.3–8.4) | 0.0 (−1.2, 1.1) | .96 | 18.0 (17.7–18.3) | 0.1 (−1.8, 2.0) | .92 | 5.3 (5.0–5.5) | −1.2 (−3.4, 1.1) | .28 | 10.8 (9.6–12.2) | 2.4 (0.9–4.0) g | .004 | 8.4 (8.2–8.6) | 1.2 (0.7–1.7) g | < .001 |
Stomach | 13 | 8.8 (8.8–8.9) | −1.8 (−2.5, −1.1) g | < .001 | 7.5 (7.4–7.6) | −1.6 (−2.0, −1.2) g | < .001 | 13.5 (13.3–13.8) | −1.9 (−2.1, −1.7 g ) | < .001 | 12.8 (12.5–13.2) | −2.9 (−3.2, −2.5) g | < .001 | 13.4 (12.0–14.8) | −2.0 (−2.9, −1.0) g | .001 | 11.9 (11.6–12.1) | −1.9 (−2.2, −1.7) g | < .001 |
Esophagus | 14 | 7.9 (7.8–8.0) | −0.2 (−0.7, 0.2) | .26 | 8.8 (8.7–8.9) | 0.3 (−0.2, 0.9) | .22 | 6.1 (5.9–6.2) | −4.6 (−4.9, −4.4) g | < .001 | 3.6 (3.4–3.8) | −1.0 (−1.8, −0.2) g | .02 | 9.5 (8.5–10.7) | 0.6 (−1.0, 2.2) | .42 | 4.9 (4.7–5.1) | −1.5 (−1.9, −1.1) g | < .001 |
Brain and other nervous system | 15 | 7.8 (7.7–7.8) | −0.3 (−0.4, −0.2) g | < .001 | 8.8 (8.8–8.9) | 0.0 (−0.1, 0.1) | .51 | 4.9 (4.7–5.1) | 0.1 (−0.3, 0.5) | .68 | 4.6 (4.4–4.8) | 0.3 (−0.3, 0.9) | .29 | 6.8 (5.9–7.8) | 1.2 (−0.4, 2.8) | .13 | 5.8 (5.6–5.9) | −0.6 (−0.9, −0.4) g | < .001 |
Thyroid | 16 | 7.4 (7.4–7.5) | −1.7 (−3.0, −0.4) g | .02 | 8.2 (8.2–8.3) | −1.7 (−3.0, −0.3) g | .02 | 3.9 (3.8–4.0) | −5.8 (−9.7, −1.8) g | .009 | 7.6 (7.4–7.9) | −0.5 (−2.8, 1.9) | .66 | 6.1 (5.3–7.0) | 4.7 (2.8–6.7) g | < .001 | 6.3 (6.2–6.5) | −0.3 (−3.7, 3.2) | .86 |
Testis | 17 | 5.8 (5.8–5.9) | 0.5 (0.4–0.7) g | < .001 | 7.1 (7.0–7.2) | 0.5 (0.3–0.7) g | < .001 | 1.6 (1.5–1.7) | 1.1 (0.4–1.7) g | .003 | 2.1 (2.0–2.3) | 2.2 (1.3–3.1) g | < .001 | 7.5 (6.6–8.4) | 2.4 (0.9–4.0) g | .004 | 5.3 (5.2–5.5) | 3.7 (2.9–4.5) g | < .001 |
Larynx | 18 | 5.5 (5.4–5.5) | −2.4 (−2.5, −2.3) g | < .001 | 5.6 (5.5–5.6) | −2.5 (−2.9, −2.0) g | < .001 | 7.9 (7.8–8.2) | −3.2 (−3.4, −2.9) g | < .001 | 2.0 (1.9–2.2) | −2.4 (−3.5, −1.3) g | < .001 | 6.7 (5.8–7.7) | −0.6 (−2.0, 0.8) | .39 | 4.5 (4.3–4.6) | −3.2 (−3.6, −2.9) g | < .001 |
Females | |||||||||||||||||||
Breast | 1 | 128.5 (128.2–128.7) | 0.5 (0.4–0.6) g | < .001 | 134.7 (134.4–135.0) | 0.6 (0.4–0.7) g | < .001 | 129.7 (129.0–130.4) | −0.3 (−1.3, 0.7) | .59 | 102.1 (101.2–103.0) | 1.9 (1.6, 2.1) g | < .001 | 119.1 (115.6–122.8) | −1.8 (−5.3, 1.9) | .31 | 98.7 (98.1–99.3) | 1.1 (0.7–1.5) g | < .001 |
Lung and bronchus | 2 | 51.0 (50.9–51.1) | −1.1 (−1.2, −0.9) g | < .001 | 56.8 (56.6–56.9) | −0.8 (−1.0, −0.7) g | < .001 | 47.8 (47.4–48.3) | −1.6 (−1.9, −1.3) g | < .001 | 28.6 (28.1–29.1) | 0.1 (−0.1, 0.3) | .33 | 61.5 (59.0–64.2) | 0.3 (−0.1, 0.8) | .14 | 23.1 (22.8–23.4) | −0.7 (−0.9, −0.5) g | < .001 |
Colon and rectum | 3 | 33.9 (33.7–34.0) | −1.2 (−1.9, −0.5) g | .001 | 33.9 (33.8–34.0) | −1.1 (−1.6, −0.7) g | < .001 | 39.1 (38.7–39.5) | −1.9 (−2.5, −1.3) g | < .001 | 26.0 (25.6–26.5) | −2.3 (−2.5, −2.0) g | < .001 | 48.4 (46.1–50.7) | −0.2 (−0.7, 0.3) | .41 | 30.0 (29.7–30.3) | 0.0 (−0.7, 0.8) | .89 |
Corpus and uterus, NOS | 4 | 27.7 (27.6–27.8) | 0.8 (−0.1, 1.7) | .07 | 28.1 (28.0–28.3) | 0.4 (−0.4, 1.1) | .32 | 28.5 (28.1–28.8) | 2.4 (2.2–2.5) g | < .001 | 21.0 (20.6–21.4) | 2.5 (2.2–2.7) g | < .001 | 29.8 (28.1–31.6) | 2.1 (1.5–2.8) g | < .001 | 25.2 (25.0–25.5) | 2.2 (1.9–2.4) g | < .001 |
Thyroid | 5 | 21.2 (21.1–21.3) | −2.9 (−3.9, −1.8) g | < .001 | 22.3 (22.2–22.4) | −3.1 (−4.4, −1.8) g | < .001 | 13.5 (13.2–13.7) | −5.3 (−7.8, −2.7) g | .001 | 22.6 (22.2–23.1) | −1.1 (−2.4, 0.2) | .08 | 21.7 (20.2–23.2) | 5.5 (4.5–6.5) g | < .001 | 23.1 (22.8–23.4) | −0.6 (−2.5, 1.4) | .55 |
Melanoma of the skin | 6 | 18.2 (18.2–18.3) | 1.8 (1.6–2.0) g | < .001 | 25.0 (24.9–25.1) | 2.4 (2.1–2.7) g | < .001 | 0.9 (0.9–1.0) | −0.9 (−1.6, −0.1) g | .03 | 1.3 (1.2–1.4) | −0.4 (−1.4, 0.6) | .42 | 9.4 (8.3–10.5) | 3.3 (2.1–4.5) g | < .001 | 4.6 (4.4, 4.7) | 0.7 (0.1, 1.3) g | .04 |
Non‐Hodgkin lymphoma | 7 | 16.3 (16.2–16.4) | −0.1 (−0.2, 0.0) g | .03 | 17.0 (16.9–17.1) | −0.2 (−0.3, 0.0) g | .01 | 12.7 (12.5–12.9) | 0.5 (0.2–0.7) g | < .001 | 11.4 (11.1–11.7) | 0.2 (−0.2, 0.7) | .28 | 16.4 (15.0–17.8) | −0.1 (−0.8, 0.7) | .83 | 15.7 (15.4, 15.9) | 0.3 (0.1–0.6) g | .005 |
Kidney and renal pelvis | 8 | 12.0 (12.0–12.1) | 1.2 (0.8–1.7) g | < .001 | 12.1 (12.0–12.2) | 1.3 (0.7–1.9) g | .001 | 13.8 (13.6–14.0) | 0.5 (0.0–1.0) g | .05 | 5.6 (5.4–5.9) | 1.4 (0.7–2.1) g | .001 | 23.4 (21.8–25.0) | 2.3 (1.4–3.2) g | < .001 | 12.3 (12.1, 12.5) | 1.6 (1.4–1.9) g | < .001 |
Leukemia | 9 | 11.9 (11.8–11.9) | 0.1 (−0.3, 0.6) g | .54 | 12.5 (12.4–12.6) | 0.2 (−0.4, 0.8) | .41 | 9.7 (9.6–9.9) | 0.1 (−0.8, 1.0) | .86 | 7.0 (6.7–7.2) | 1.2 (0.8–1.6) g | < .001 | 11.0 (9.9–12.1) | 1.6 (0.4–2.9) g | .01 | 10.1 (9.9, 10.3) | 1.0 (0.7–1.3) g | < .001 |
Pancreas | 10 | 11.6 (11.5–11.7) | 1.0 (1.0–1.1) g | < .001 | 11.4 (11.3–11.5) | 1.1 (1.0–1.2) g | < .001 | 15.2 (15.0–15.5) | 0.7 (0.5–1.0) g | < .001 | 9.0 (8.7–9.2) | 0.8 (0.5–1.1) g | < .001 | 12.6 (11.4–13.8) | 1.0 (0.0–2.1) g | .05 | 10.5 (10.3–0.7) | 0.9 (0.6–1.1) g | < .001 |
Ovary | 11 | 10.9 (10.9–11.0) | −2.5 (−3.5, −1.5) g | < .001 | 11.3 (11.2–11.4) | −2.9 (−4.2, −1.7) g | < .001 | 9.0 (8.8–9.2) | −1.0 (−1.3, −0.7) g | < .001 | 9.4 (9.2–9.7) | −0.2 (−0.6, 0.1) | .22 | 13.1 (11.9–14.3) | −0.3 (−1.5, 1.0) | .68 | 10.0 (9.9–10.2) | −1.2 (−1.5, −1.0) g | < .001 |
Urinary bladder | 12 | 8.6 (8.5–8.6) | −0.9 (−1.1, −0.8) g | < .001 | 9.6 (9.6–9.7) | −0.7 (−0.9, −0.6) g | < .001 | 6.7 (6.5–6.8) | −0.6 (−0.8, −0.3) g | < .001 | 3.7 (3.5–3.9) | −0.7 (−1.4, 0.0) g | .04 | 6.5 (5.6–7.4) | 1.7 (0.2–3.1) g | .03 | 5.0 (4.8–5.1) | −1.1 (−1.5, −0.6) g | < .001 |
Cervix | 13 | 7.9 (7.8–7.9) | 0.1 (−2.5, 2.8) | .92 | 7.4 (7.3–7.5) | 0.1 (−2.8, 3.1) | .95 | 9.0 (8.8–9.2) | −1.7 (−2.2, −1.2) g | < .001 | 6.2 (6.0–6.5) | −1.5 (−2.1, −0.9) g | < .001 | 11.5 (10.4–12.7) | 0.5 (−0.4, 1.4) | .27 | 9.9 (9.8–10.1) | 0.3 (−0.9, 1.5) | .61 |
Oral cavity and pharynx | 14 | 6.6 (6.5–6.6) | 0.5 (0.4–0.6) g | < .001 | 7.2 (7.1–7.3) | 0.9 (0.7–1.0) g | < .001 | 5.2 (5.0–5.3) | −0.7 (−1.0, −0.5) g | < .001 | 5.3 (5.1–5.5) | 0.1 (−0.6, 0.7) | .82 | 7.0 (6.2–7.9) | 0.5 (−1.1, 2.1) | .52 | 4.5 (4.3–4.6) | 0.5 (0.0–1.0) | .06 |
Myeloma | 15 | 6.0 (6.0–6.1) | 1.4 (1.0–1.7) g | < .001 | 5.1 (5.0–5.1) | 1.0 (0.5–1.5) g | .002 | 13.3 (13.1–13.5) | 2.1 (1.8–2.4) g | < .001 | 3.3 (3.1–3.5) | 0.9 (0.3–1.6) g | .006 | 7.8 (6.9–8.8) | 1.4 (−0.1, 2.9) | .07 | 6.1 (6.0–6.3) | 2.2 (1.5–2.8) g | < .001 |
Brain and other nervous system | 16 | 5.6 (5.5–5.6) | −0.5 (−0.7, −0.3) g | < .001 | 6.4 (6.3–6.4) | −0.3 (−0.5, −0.1) g | .008 | 3.6 (3.5–3.7) | −0.4 (−0.8, 0.0) | .07 | 3.3 (3.2–3.5) | 0.3 (−0.3, 0.8) | .32 | 4.7 (4.1–5.5) | 0.7 (−1.3, 2.8) | .45 | 4.6 (4.5–4.7) | −0.3 (−0.7, 0.0) | .06 |
Liver and intrahepatic bile duct | 17 | 4.8 (4.7–4.8) | 1.6 (0.3–3.0) g | .02 | 4.0 (4.0–4.1) | 3.8 (3.5–4.1) g | < .001 | 5.6 (5.5–5.8) | 0.7 (−1.9, 3.3) | .59 | 7.3 (7.0–7.5) | −4.6 (−7.7, −1.4) g | .009 | 11.8 (10.7–12.9) | 3.3 (2.0–4.6) g | < .001 | 7.9 (7.7–8.0) | 2.3 (2.0–2.6) g | < .001 |
Stomach | 18 | 4.7 (4.7–4.8) | 0.1 (−0.2, 0.4) | .36 | 3.5 (3.5–3.6) | 0.0 (−0.5, 0.4) | .83 | 7.6 (7.4–7.7) | −1.2 (−1.4, −0.9) g | < .001 | 7.5 (7.3–7.8) | −2.6 (−3.1, −2.2) g | < .001 | 7.9 (7.0–8.9) | −0.3 (−1.6, 1.1) | .68 | 7.7 (7.5–7.8) | −1.0 (−1.4, −0.7) g | < .001 |
Children | |||||||||||||||||||
Leukemia | 5.3 (5.2–5.4) | 0.7 (0.4–1.0) g | < .001 | 5.2 (5.1–5.4) | 0.5 (0.3–0.8) g | .001 | 3.3 (3.1–3.5) | 1.2 (0.6–1.7) g | < .001 | 5.8 (5.4–6.1) | 1.1 (0.4–1.8) g | .006 | 6.6 (5.6–7.9) | 1.0 (−1.0, 2.9) | .31 | 6.4 (6.2–6.6) | 0.8 (0.3–1.2) g | .002 | |
Brain and other nervous system | 3.8 (3.7–3.9) | 0.7 (0.4–1.0) g | < .001 | 4.3 (4.2–4.4) | 0.8 (0.5–1.2) g | < .001 | 3.0 (2.8–3.2) | 1.3 (0.7–2.0) g | < .001 | 3.1 (2.8–3.3) | 1.4 (0.4–2.4) g | .01 | 3.6 (2.8–4.5) | — h | 3.1 (2.9–3.2) | 0.1 (−0.3, 0.5) | .62 | ||
Lymphoma | 1.7 (1.6–1.7) | 0.9 (0.6–1.3) g | < .001 | 1.7 (1.7–1.8) | 1.0 (0.4–1.5) g | .001 | 1.6 (1.5–1.8) | 1.4 (0.6–2.1) g | .001 | 1.6 (1.4–1.8) | 1.0 (−0.2, 2.3) | .09 | 1.5 (1.0–2.1) | — h | 1.5 (1.4–1.6) | 0.2 (−0.3, 0.7) | .35 | ||
AYAs | |||||||||||||||||||
Thyroid | 12.0 (11.9–12.0) | −2.0 (−3.6, −0.3) g | .02 | 13.6 (13.4–13.7) | −2.7 (−4.5, −0.7) g | .007 | 5.5 (5.3–5.6) | −6.0 (−9.7, −2.2) g | .005 | 12.7 (12.3–13.0) | 0.1 (−1.7, 1.9) | .92 | 13.2 (11.8–14.6) | 5.2 (4.1–6.3) g | < .001 | 10.8 (10.6–11.0) | 0.7 (−2.7, 4.3) | .65 | |
Female breast | 22.8 (22.6–23.0) | 1.0 (0.6–1.4) g | < .001 | 23.5 (23.2–23.7) | 0.6 (0.5–0.8) g | < .001 | 27.0 (26.5–27.6) | 0.3 (0.1–0.6) g | .02 | 20.4 (19.8–21.1) | 0.9 (0.5–1.4) g | < .001 | 21.7 (19.2–24.4) | 1.3 (−0.2, 2.8) | .10 | 18.3 (17.9–18.7) | 1.8 (0.9–2.8) g | .001 | |
Lymphoma | 7.7 (7.6–7.8) | −0.4 (−0.5, −0.3) g | < .001 | 8.2 (8.1–8.3) | −0.4 (−0.6, −0.3) g | < .001 | 8.3 (8.1–8.5) | −0.8 (−1.3, −0.4) g | .001 | 5.6 (5.3–5.8) | 2.0 (1.6–2.5) g | < .001 | 6.0 (5.2–7.0) | 1.4 (−0.6, 3.4) | .17 | 6.2 (6.1–6.4) | 0.8 (0.0–1.7) g | .05 | |
Melanoma of the skin | 6.7 (6.6–6.7) | −0.8 (−1.2, −0.5) g | < .001 | 10.6 (10.4–10.7) | −0.5 (−1.0, 0.0) g | .05 | 0.2 (0.2–0.3) | −1.8 (−3.4, −0.1) g | .04 | 0.5 (0.4–0.6) | −1.7 (−3.2, −0.3) g | .02 | 4.1 (3.3–5.0) | 0.8 (−0.8, 2.4) | .29 | 1.2 (1.2–1.3) | −1.6 (−2.2, −0.9) g | < .001 | |
Testis | 11.1 (11.0–11.3) | 0.8 (0.6–0.9) g | < .001 | 13.5 (13.3–13.7) | 0.5 (0.3–0.7) g | < .001 | 2.6 (2.5–2.8) | 0.8 (−0.2, 1.7) | .10 | 4.2 (3.9–4.5) | 2.8 (1.7–3.8) g | < .001 | 14.6 (12.7–16.7) | 1.3 (−0.1, 2.7) | .07 | 11.6 (11.3–11.8) | 3.0 (2.7–3.4) g | < .001 | |
Colon and rectum | 5.1 (5.0–5.2) | 5.0 (3.7–6.4) g | < .001 | 5.6 (5.5–5.7) | 3.2 (0.8–5.7) g | .009 | 4.9 (4.8–5.1) | 3.1 (2.1–4.1) g | < .001 | 3.4 (3.2–3.6) | 1.2 (0.3–2.1) g | .01 | 7.6 (6.6–8.8) | 3.4 (1.2–5.6) g | .005 | 4.1 (4.0–4.3) | 8.4 (6.1–10.8) g | < .001 |
Abbreviations: AAPC, average annual percent change; AI/AN, American Indian/Alaska Native; APC, annual percent change; API, Asian/Pacific Islander; AYA, adolescents and young adults; NOS, not otherwise specified; PRCDA, Indian Health Service Purchased/Referred Care Delivery Area.
Rates are per 100,000 persons and were age standardized to the 2000 US standard population (19 age groups; US Bureau of the Census. Current Population Report P25‐1130. US Government Printing Office; 2000).
The AAPC is the average APC and is a weighted average of the APCs over the fixed interval 2014–2018 using the underlying joinpoint model for the period of 2001–2018. Joinpoint models with up to three joinpoints are based on rates per 100,000 persons and are age standardized to the 2000 US standard population (19 age groups; US Bureau of the Census, Current Population Report P25‐1130; National Cancer Institute; Joinpoint Regression Program, version 4.9.0.0; Surveillance Research Program, National Cancer Institute; 2021).
Cancers are sorted in descending order according to sex‐specific rates for all racial/ethnic groups. More than 15 cancers may appear under males and females to include the top 15 cancers in every racial/ethnic group.
White, Black, API, and AI/AN (PRCDA 2017 counties) include non‐Hispanic; the racial/ethnic categories are mutually exclusive.
Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program areas reported by the North American Association of Central Cancer Registries as meeting high‐quality incidence data standards for the specified time periods. Registries included in the joinpoint models (2001–2018) for all racial/ethnic groups, White, Black, AI/AN, API, Hispanic, and non‐Hispanic (46 states): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming. Registries included in the incidence rates (2014–2018) for all racial/ethnic groups, White, Black, AI/AN, API, Hispanic, and non‐Hispanic (49 states, the District of Columbia, and one territory): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
For all sites, myelodysplastic syndromes are included for the rate and APC calculations; they are excluded from cancer‐specific analysis. Ovary excludes borderline tumors.
The AAPC is statistically significantly different from zero (two‐sided p < .05).
The statistic could not be calculated. The AAPC is based on <10 cases for at least 1 year within the time interval.